{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms+by+Histologic+Type", "query": { "condition": "Neoplasms by Histologic Type" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 20821, "total_pages": 2083, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms+by+Histologic+Type&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T20:58:27.889Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00913913", "title": "Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "DC vaccine", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "IFN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2009-02", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2015-12-01", "last_synced_at": "2026-05-21T20:58:27.889Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00913913" }, { "nct_id": "NCT00569660", "title": "Ph II Study of Azacitidine in Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2005-06", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2012-08-07", "last_synced_at": "2026-05-21T20:58:27.889Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00569660" }, { "nct_id": "NCT02553460", "title": "Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "ITMHA", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Asparaginase Erwinia Chrysanthemi", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "365 Days", "sex": "ALL", "summary": "Up to 365 Days" }, "enrollment_count": 50, "start_date": "2016-01-29", "completion_date": "2031-10", "has_results": true, "last_update_posted_date": "2025-12-10", "last_synced_at": "2026-05-21T20:58:27.889Z", "location_count": 9, "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02553460" }, { "nct_id": "NCT00002860", "title": "SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "1996-11", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2012-01-13", "last_synced_at": "2026-05-21T20:58:27.889Z", "location_count": 124, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 81 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002860" }, { "nct_id": "NCT00941720", "title": "Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2009-06-11", "completion_date": "2013-02-28", "has_results": true, "last_update_posted_date": "2020-07-24", "last_synced_at": "2026-05-21T20:58:27.889Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00941720" }, { "nct_id": "NCT00104923", "title": "Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "fenretinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Cancer Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 29, "start_date": "2005-02", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-07-19", "last_synced_at": "2026-05-21T20:58:27.889Z", "location_count": 4, "location_summary": "Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104923" }, { "nct_id": "NCT05143996", "title": "CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome (MDS)" ], "interventions": [ { "name": "CLN-049", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cullinan Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-11-18", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-05-21T20:58:27.889Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Los Angeles, California • Miami, Florida + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05143996" }, { "nct_id": "NCT03945162", "title": "Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Unresponsive/Intolerant to BCG" ], "interventions": [ { "name": "Ruvidar® (TLD-1433) bladder infusion and PDT", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Theralase® Technologies Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2019-08-30", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-05-21T20:58:27.889Z", "location_count": 10, "location_summary": "Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Greenwood", "state": "Indiana" }, { "city": "Syracuse", "state": "New York" }, { "city": "Gahanna", "state": "Ohio" }, { "city": "Bala-Cynwyd", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03945162" }, { "nct_id": "NCT02370342", "title": "Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Renal Carcinoma", "Renal Mass" ], "interventions": [ { "name": "Robot-Assisted Laparoscopic Surgery", "type": "PROCEDURE" }, { "name": "High-Intensity Focused Ultrasound Ablation", "type": "PROCEDURE" }, { "name": "Therapeutic Laparoscopic Surgery", "type": "PROCEDURE" }, { "name": "Sonatherm 600i Ultrasonic Lesion Generating System", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "DEVICE" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-12-18", "completion_date": "2019-12-18", "has_results": false, "last_update_posted_date": "2017-12-20", "last_synced_at": "2026-05-21T20:58:27.889Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02370342" }, { "nct_id": "NCT02020941", "title": "Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma" ], "interventions": [ { "name": "carfilzomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Attaya Suvannasankha", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2013-09", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-05-21T20:58:27.889Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02020941" } ] }